MIMETAS Revenue and Competitors
Estimated Revenue & Valuation
- MIMETAS's estimated annual revenue is currently $22.1M per year.
- MIMETAS's estimated revenue per employee is $204,630
Employee Data
- MIMETAS has 108 Employees.
- MIMETAS grew their employee count by 2% last year.
MIMETAS Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $2.9M | 20 | 11% | N/A | N/A |
#2 | $35.9M | 160 | 20% | N/A | N/A |
#3 | $5.6M | 34 | 31% | N/A | N/A |
#4 | $4.6M | 28 | 4% | N/A | N/A |
#5 | $5.6M | 34 | -3% | N/A | N/A |
#6 | $22.1M | 108 | 2% | N/A | N/A |
#7 | $2.9M | 20 | 11% | N/A | N/A |
#8 | $20.6M | 101 | 16% | N/A | N/A |
#9 | $65M | 287 | 34% | $31.5M | N/A |
What Is MIMETAS?
High-throughput Human Disease and Tissue Models MIMETAS BV develops organ-on-a-chip tissue models for evaluating drugs, chemicals and food components. Its unique microfluidic technology, designated OrganoPlates®, enables testing of compounds in high-throughput on miniaturized organ models. These models show better predictivity as compared to laboratory animals and conventional cell culture models. The OrganoPlate® platform supports 3D cell culture under continuous perfusion and membrane-free co-culture, including epithelial and endothelial boundary tissues. MIMETAS offers OrganoPlates®, develops and validates customised disease, toxicology and transport models and will ultimately make her technology available for personalised therapy selection.
keywords:N/A
N/A
Total Funding
108
Number of Employees
$22.1M
Revenue (est)
2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
MIMETAS News
CN Bio Tissues, Mimetas Insphero, Ascendance Bio, Kirkstall , Hurel , Synvivo , Axosim and Nortis. This Organs-on-chips Market report covers...
LEIDEN, The Netherlands, April 19, 2022 / B3C newswire / -- MIMETAS, a global leader in organ-on-chip-based disease models, is a partner in...
Mimetas BV participating in 325m cancer funding. © Oncode Institute. 20.04.2022 by tg. Organ-on-chip disease model specialist Mimentas BV participates in a...
Emulate, CN Bio, Tissuse, Mimetas, Insphero, Ascendance Bio, Kirkstall, Hurel, Synvivo, Axosim, Nortis. Geographical Analysis: North America, ...
... Analysis, Technology and Global Industry Trends by 2027 Top Key Vendors-REPROCELL, 3D Biotek, Nano3D Biosciences, MIMETAS.
Other Companies in Leiden
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $18.2M | 120 | 38% | N/A |
#2 | $39.2M | 164 | 17% | N/A |
#3 | $35M | 189 | 20% | N/A |
#4 | $15M | 223 | 77% | N/A |
#5 | $7.5M | 316 | 55% | N/A |